BIVI שווי כולל של נכסי החברה BioVie Pharma

The market price confirmed by the chart shows BioVie Inc. (BIVI) total assets at 17.94. The business relies on exclusive rights for combating liver inflammation, which, combined with strict FDA oversight, limits competition. BioVie Inc. (BIVI) is also building intellectual capital for dementia therapy; however, contractor errors during testing have triggered litigation and an acute liquidity shortage.

A comparative analysis of total resources allows investors to assess the scale of the business, where this metric, calculated inversely via ROA, captures the total value of the organization's assets and liabilities. The trend in the company's total assets reflects the capitalization of intellectual property and the costs of clinical trials for the NE3107 molecule, determining the potential for future licensing deals for BioVie Inc. (BIVI).